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Abstract
Background: Increasingly, biomedical researchers are encouraged or required
by research funders and journals to share their data, but there's very little
guidance on how to do that equitably and usefully, especially in
resource-constrained settings. We performed an in-depth case study of one
data sharing pioneer: the WorldWide Antimalarial Resistance Network
(WWARN).
Methods: The case study included a records review, a quantitative analysis of
WAARN-related publications, in-depth interviews with 47 people familiar with
WWARN, and a witness seminar involving a sub-set of 11 interviewees.
Results: WWARN originally aimed to collate clinical, in vitro, pharmacological
and molecular data into linked, open-access databases intended to serve as a
public resource to guide antimalarial drug treatment policies. Our study
describes how WWARN navigated challenging institutional and academic
incentive structures, alongside funders' reluctance to invest in capacity building
in malaria-endemic countries, which impeded data sharing. The network
increased data contributions by focusing on providing free, online tools to
improve the quality and efficiency of data collection, and by inviting
collaborative authorship on papers addressing policy-relevant questions that
could only be answered through pooled analyses. By July 1, 2016, the
database included standardised data from 103 molecular studies and 186
clinical trials, representing 135,000 individual patients. Developing the
database took longer and cost more than anticipated, and efforts to increase
equity for data contributors are on-going. However, analyses of the pooled data
have generated new methods and influenced malaria treatment
recommendations globally. Despite not achieving the initial goal of real-time
surveillance, WWARN has developed strong data governance and curation
tools, which are now being adapted relatively quickly for other diseases.
Conclusions: To be useful, data sharing requires investment in long-term
infrastructure. To be feasible, it requires new incentive structures that favour the
generation of reusable knowledge.
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Introduction
In recent years, some academic journals have begun to encourage 
or require researchers to make the data underlying published 
papers available to the scientific community for re-use1–3. At the 
same time, several major funders of biomedical research have 
begun to encourage or require grant-holders to share their data with 
other researchers4.
These developments are motivated partly by a desire to maxim-
ise transparency in clinical trials and other research, and partly in 
the hope of speeding up discoveries that contribute to improving 
health. This second motivation rests on the belief that data shared 
will become data reused; the combination of data generated by 
different studies will allow for more powerful meta-analysis of 
complex questions; these analyses will in turn translate into 
better policies and practice and thus to better health, at limited 
additional cost. Squeezing more knowledge out of existing data is 
considered especially important for the often neglected diseases 
that affect people in poorer countries, where most research is 
funded by public agencies or charities, and for the infectious 
disease outbreaks that most commonly occur in those countries5.
However, the many institutions now actively promoting data 
sharing give very little guidance on exactly how data should be 
shared in order to maximise health gains, in part because they 
have little systematic information on what works, what doesn’t, 
and why. Many opinions have been aired about the potential 
advantages and dangers of different models6–11, and some 
empirical studies have examined experience with sharing data 
in well-resourced areas such as cancer, or cutting-edge scientific 
fields such as neuroimaging and genomics12–17. In most areas of 
tropical medicine, the potential financial rewards for generat-
ing new information through data pooling are more limited, and 
entrenched inequities in scientific and material resources add an 
additional layer of complexity. We are not aware of any published 
study examining in detail the experience of sharing individual 
patient level data generated in clinical trials conducted in low and 
middle income settings.
This paper seeks to begin to fill that gap by providing an in-depth 
case study of the development of the WorldWide Antimalarial 
Resistance Network (WWARN), one of the earliest networks 
sharing clinical trial data involving scientists from research 
institutions in low, middle and high income countries.
WWARN (referred to until 2010 as WARN) was an initiative 
of senior academic researchers working in the field of malaria 
who were concerned about the spread of antimalarial resistance. 
The network’s aim was to bring together individual patient and 
parasite-level data in four areas - clinical, in vitro, molecular and 
pharmacological - to allow for the rapid tracking of and response 
to drug-resistant malaria18. Data on the quality of antimalarial 
medicine was added in 2010.
The idea of bringing four different markers of antimalarial 
resistance data together into a single global database was first 
mooted in 2004 and was developed opportunistically, at infor-
mal side-meetings attached to scientific conferences which were 
attended by academics as well as technical experts from the 
World Health Organization (WHO) and other global health 
bodies. Clinical data were expected to include measures of drug 
efficacy (e.g. treatment failure by day 28 or 42) for individual 
patients drawn from clinical trials performed by academic research-
ers as well as from therapeutic efficacy studies conducted by 
national malaria programmes as part of their routine surveillance 
activities. In 2007, the Bill and Melinda Gates Foundation (BMGF) 
provided grants totalling close to US$ 1.1 million to the found-
ing members to further develop the concept. BMGF invested a 
further US$ 20.6 million in the network in 2009, simultaneously 
approving a linked grant of US$7.5 million to the WHO to support 
surveillance of the therapeutic efficacy of antimalarials in endemic 
countries. That year, WWARN was established as a formal entity 
with a secretariat based at the University of Oxford. WWARN 
was conceived not as a formal consortium of research sites, but as 
a network of interested researchers. The scientific director was 
based in Seattle, while heads of the other scientific modules 
(clinical, pharmacology, in vitro, molecular, informatics and later 
medicine quality) were based, respectively, at universities or 
labs in Darwin, Cape Town, Paris/Phnom Penh, Oxford and 
Vientiane.
Using a number of qualitative methods, we examined the evolu-
tion of the network, focusing in particular on issues that facilitated 
or impeded the sharing of data, and the use of data that had been 
shared. The study, performed at the request of the Public Health 
Research Data Forum, was not designed as an evaluation of 
WWARN, nor did it intend to probe all aspects of scientific col-
laborations. Rather, we aimed to contribute to an evidence-based 
understanding of the factors that make sharing of patient-level 
data feasible and useful, particularly when research is conducted 
in low and middle income countries. A full technical report was 
prepared for research funders19; here we focus on findings we 
believe to be of greatest interest to researchers who share data, or 
are contemplating doing so.
Methods
The case study included a records review, a quantitative analysis of 
publications by WWARN and its collaborators, a series of in-depth 
interviews, and a witness seminar.
Records review
For the records review, a WWARN administrator who has main-
tained records since the outset of the collaboration provided access 
to grant proposals and grant-related reporting forms; progress 
reports by scientific module heads, internal strategic plans and busi-
ness plans; minutes of all board and Scientific Advisory Committee 
(SAC) meetings; iterations of terms of submission, memoranda of 
understanding and contracts with data providers; correspondence 
with the World Health Organization (WHO) and other key partners; 
and surveys of user and stakeholder attitudes. WWARN founders 
provided us with archives of conference presentations, includ-
ing those made at formal and informal side meetings to malaria 
or infectious disease conferences. The network provided analytics 
data covering use of the WWARN website, downloads of tools, and 
social media reach. We also searched for published papers mention-
ing WWARN.
Page 3 of 22
Wellcome Open Research 2017, 2:63 Last updated: 03 OCT 2017
These documents were read by two investigators and evaluated for 
relevance to the experience of data sharing. Salient information was 
consolidated into a timeline. Documents considered to be highly 
relevant by either investigator were processed as below.
Quantitative analysis of publications
All papers published using data from the WWARN repository 
as well as those listed on the WWARN website’s “Impact” page 
(http://www.wwarn.org/impact/publications) to end-June 2016 
were entered into a database. For each paper we included the type 
of paper (coded by SB), its citation count, the regional and institu-
tional affiliation of first and last authors, if any (some of the pooled 
analyses were published in the name of the study group as a whole) 
and the total number of authors on the paper.
In-depth interviews
The principal investigator (EP) conducted interviews, generally of 
60–90 minutes in length, with individuals purposely selected to 
give a wide variety of perspectives on WWARN’s evolution. 
Potential interviewees were contacted by email with information 
about the purpose of the study and the broad areas of questioning 
to be covered, and invited to participate. Those who agreed were 
provided with more detailed information prior to the interview, 
and signed consent forms (protocol available at doi:  10.7910/DVN/
V1TKIO20). Interviews were conducted in English, French or Indo-
nesian, face-to-face or via Skype, between May and July 2016.
Comprehensive notes were taken during all interviews, and where 
consent was given for recording, interviews were audio-recorded.
Witness seminar
A subset of interviewees participated in a witness seminar, a 
format which encourages debate about how and why a recent 
set of events evolved as they did. This collective reflection often 
prompts memories and spotlights issues which don’t arise in indi-
vidual interviews; it provides an opportunity to validate or revisit 
data gathered in those interviews21. The participants were purpo-
sively selected to reflect a combination of institutional memory 
and current experience, as well as to ensure participation from 
malaria endemic and non-endemic countries; our choice was also 
influenced by opportunism and cost-effectiveness: nine of the 11 
participants were already planning to gather for a conference. 
All participants signed forms consenting to the recording of the 
seminar, and the use of the data for the purposes of this study. 
The four-hour seminar, which took place on June 23 2016, was 
chaired by two independent researchers, who were provided with 
a detailed issues brief by the study PI (EP). It was recorded and 
transcribed by a third party.
Data handling
Notes and relevant documents from the records review, as well as 
the notes or transcripts of all in-depth interviews and the transcript 
of the witness seminar were entered into NVivo software Version 
11.3.2. (QSR International) and coded thematically by the principal 
investigator (EP). The coding tree, which provides both our cod-
ing categories and brief descriptions of the areas they cover, can 
be downloaded at doi: 10.7910/DVN/V1TKIO20. High order codes 
were deductive, derived from the original study protocol, which 
can also be found at doi: 10.7910/DVN/V1TKIO20. These include 
broad topic areas such as history and evolution of the network, 
institutional relationships, equity and incentives. Further codes 
were developed inductively from the content of the data them-
selves (for example, under “Policies and Practice” we coded for 
terms of submission and access, institutional governance, infor-
matics, data management and other relevant terms). We refined 
these iteratively as data analysis progressed. Thematic analysis 
was carried out using a modified version of the iterative categori-
zation method described by Joanne Neale22.
The study was approved by the Oxford Tropical Research Ethics 
Committee (OxTREC Reference: 593-16). More details related 
to methods are provided in COREQ file at doi: 10.7910/DVN/
V1TKIO20, which follows the COREQ guidelines for reporting 
qualitative research23.
Results
Data and participants
We identified over 685 documents or presentations relating to 
WWARN, its history and evolution. After removing multiple drafts 
and near-duplicates and filtering for content most relevant to data 
sharing, we entered approximately 13% of all documents into 
NVivo for detailed coding.
Our database of academic publications by the WWARN 
network and WWARN-related papers by collaborators included 
a total of 77 papers; 18 of these were publications analysing data 
contained in the WWARN database, which we term “core” 
WWARN publications.
We interviewed 47 individuals. Many research participants with 
functional roles such as science group head, scientific advisory 
committee member or board member also serve on advisory boards 
for treatment guidelines and other policy issues at the national or 
international level, and most also contribute data to the database. 
Many other data contributors similarly have dual roles as policy 
advisers.
Table 1 groups respondents by their most formal relationship 
to WWARN, if any, otherwise by their primary professional 
affiliation. Thus, a WWARN board member who is also a policy 
maker is listed as a board member, while a researcher who 
contributes data to the WWARN database and also sits on a 
malaria control programme advisory panel is listed as a data 
contributor.
Twenty-one of the interviewees were women, and 11 were from low 
or middle income countries. Some 46% were based in Europe at the 
time of their involvement with WWARN, with the remainder evenly 
split between Asia/Australasia, Africa and North America.
Eleven of the interviewees also participated in the witness 
seminar. Of these, four were women, and four were from low or 
middle income countries. They comprised three current WWARN 
staff, three board or SAC members (two of whom are active data 
contributors), three science group heads, one former employee of a 
global health organisation and one other data contributor.
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No-one refused participation point-blank, and no-one who engaged 
in an interview terminated it. However five individuals failed to 
respond to repeated approaches by e-mail: two former employees 
of WWARN; one current and one former employee of the World 
Health Organization; and a policy-maker in a malaria-endemic 
country. A further two individuals, both senior researchers based 
in malaria-endemic countries, agreed to be interviewed but were 
unable to make any of the repeatedly-scheduled interview times. 
Three participants scheduled to participate in the witness seminar 
did not participate, one for personal reasons and two because of dif-
ficulties getting visas to the UK.
The early phase of WWARN’s development
Early intentions. In 2006, Carol Sibley, a professor of genome 
sciences at the University of Washington, and Pascal Ringwald, a 
WHO official responsible for surveillance of malaria resistance, 
published a paper advocating for the development of a shared data 
resource to track malaria resistance. They envisaged:
“[…] a dynamic, open access database that would include cur-
rent and historical data on clinical efficacy, in vitro responses and 
molecular markers related to drug resistance in Plasmodium falci-
parum and Plasmodium vivax. The goal is to include historical and 
current data on resistance to commonly used drugs […] and on the 
many combinations that are now being tested in different settings. 
The database will be accessible to all on the Web.”18
A year later, a series of four papers published in Malaria 
Journal envisaged a “comprehensive efficacy and resistance data-
base [which] will provide malaria control managers, surveillance 
programs and policymakers with prompt access to up-to-date 
evidence of temporal and geographic trends in antimalarial drug 
resistance at the global scale.”24
In many early presentations, promoters of the concept described the 
venture as a public good which would allow policy-makers to take 
quick action to avert or limit treatment failure by adapting antima-
larial regimens as necessary.
Meeting different needs. Among interviewees, well-established 
academics from wealthy countries and the staff of global health 
organisations were particularly likely to see the global tracking of 
resistance as an important and useful goal. Several used the term 
“no-brainer” in describing the project. In other words, they believed 
the rapid compilation of research and surveillance data would self-
evidently add value to the research itself, because it would allow 
policy-makers to see the “big picture” sooner and more easily. 
Policy-makers in endemic countries were less likely to see a global 
database as helpful. Those we spoke to said they tended to look to 
the WHO for guidance on drug efficacy - a point also mentioned by 
many endemic country researchers. Further, programme managers 
said most of their concerns were localised and operational.
“The other thing that comes up with local stakeholders is the issue 
of relevance. Say I’m in an area with a lot of resistance to a drug, 
and you analyse pooled data, lots of which were collected in an 
area where resistance to that drug is not an issue, what sort of 
information will you be providing? How will local confounders be 
dealt with when you have millions of data points, the majority of 
which are irrelevant to your own setting?” 
[I28, Endemic country policy maker]
Although researchers from the same country confirmed that 
policy-makers tended to give great weight to local studies, they 
noted that cross-country meta-analyses also had a role in shap-
ing programme managers’ opinion, in two rather less direct ways. 
Firstly, national researchers often drew on WWARN analyses to 
inform the questions they asked locally, and to contextualise and 
add weight to their own site-specific findings when presenting 
them to policy makers. Secondly, analyses of pooled individual 
patient data have fed directly into the WHO guidelines, which are 
so influential in malaria-endemic countries.
National malaria programme managers are referred to as a core 
constituency in all of WWARN’s foundational documents, but 
there’s little recorded evidence of direct consultation with them 
about their needs. In October 2006, in the first meeting called 
expressly with a view to discussing WWARN, presentation notes 
record “Inform policy making process” as the first aim of the 
network, with the note “WHO has more command of this than 
researchers – [they] need to be on board if Africa is to accept.”
In meetings with WWARN held to discuss the linked grants 
provided by BMGF, the WHO repeatedly stressed its role as 
the bridge between the network and national programmes. A 
memorandum of understanding between the two organisa-
tions signed on June 10 2009 and provided to BMGF effectively 
barred WWARN from working directly with national malaria 
Table 1. Characteristics of people interviewed for 
this study.
Principal relationship to WWARN Number of interviewees
Current WWARN staff/consultant 5
Former WWARN staff/consultant 7
Current or former scientific leaders 
or group head 5
WWARN board members 3
WWARN scientific advisory 
committee members 2
Data contributors from industry 2
Other data contributors 3
Malaria researchers who do not 
contribute data 3
Secondary user or analyst 4
Current or former global health 
organisation staff 11
National policy maker 2
TOTAL 47
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programmes. One provision specifically denies WWARN 
permission “to interfere in, or duplicate, in any way, WHO’s role 
… with respect to: (a) monitoring drug efficacy (in vivo); (b) use 
of evidence for the generation of global treatment policies: and 
(c) technical advice to countries to update national treatment 
policies.” 
As a result, direct consultation with national policy makers was lim-
ited. In a meeting of the Scientific Advisory Committee (SAC) as 
late as June 2010, one endemic country researcher commented:
“Our group is weighted towards scientists. But our purpose is to do 
something about malaria. We’re waiting until quite late to figure out 
how to make the information useful to decision makers.”
(D48, Scientific Advisory Committee member)
In the same meeting, a WWARN science group head commented:
“What we decide is important, may be completely irrelevant to our 
target stakeholders. We do need to determine stakeholder needs, to 
ensure that we don’t just build a resource for ourselves.” 
(I12, WWARN science group head)
Foundational decisions about data submission. Minutes of 
project meetings show that in Oxford, an informatics team began 
to develop a database, including data intake and standardisation 
tools. They worked very largely with post-publication datasets 
provided by WWARN associates (mostly science group heads, 
SAC or board members) who had well established positions in 
globally recognised academic institutions or who came from non-
governmental organisations.
In addition to gathering and entering patient-level data from pub-
lished research studies, the intention was ultimately to populate the 
database with patient-level information from two additional sources: 
on-going (as yet unpublished) clinical trials or molecular studies, 
and treatment efficacy surveys carried out by national malaria pro-
grammes as part of their routine surveillance efforts. Some of the 
treatment efficacy surveys were funded by BMGF through a WHO 
surveillance support scheme which Foundation staff said aimed 
specifically to improve the quality and volume of data available for 
pooled analyses.
The effort to gather data from researchers in endemic countries 
was led by WWARN regional staff based in Bangkok, Nairobi, 
Dakar and Sao Paulo. They contacted authors of published studies 
and their colleagues, asking them to contribute research datasets, 
including individual patient or parasite-level data, to the network.
In countries where WHO was supporting resistance surveillance 
with funds from BMGF, the global body made the same request 
to national malaria programmes. WHO asked governments to 
sign a letter giving express permission to share data from thera-
peutic efficacy studies carried out for surveillance purposes with 
WWARN; the WHO also specifically renounced all responsibility 
for any loss or damage caused by Oxford’s handling of national 
data or specimens.
The result of all of these efforts was disappointing, according to 
many interviewees, with very few national programmes or individ-
ual researchers choosing to contribute information to the resource:
“We were not exactly flooded with data.”
(I12, WWARN science group head)
Historical context: data sharing professionally unrewarding. 
All interviewees underlined the historical context. By the time 
WWARN was set up, funders had begun to mandate sharing of 
data in the field of genomics, and demographic and health 
data collected under contract for programmes such as the Demo-
graphic and Health Survey were also routinely anonymised and 
shared. However, there were still very few examples of successful 
sharing of individual patient data in clinical medicine, especially 
in lower-income settings, and virtually none outside of closed 
consortia. According to one interviewee, many researchers were 
viscerally opposed to data sharing:
“Seven years ago, “data sharing” was a swear word.”
(I31, Current WWARN employee)
All WWARN’s early documentation described the shared resource 
as “open access”. At the time, the phrase was used largely to 
refer to making scientific papers freely available to anyone with 
an internet connection. The 2009 grant application stated that 
research tools, as well as the output of any mapping, analysis or 
other research using the database, would be openly available to 
all-comers. Although WWARN founders said in interviews that 
the intention was never to share individual level data openly, this 
may not have been obvious to the endemic country investigators 
who had data to contribute. Draft terms of submission began to 
circulate in 2010, though they were not finalised and formally 
available to potential contributors until March 2011. This was 
in part because of the considerable time that it took WWARN 
secretariat staff to persuade Oxford University lawyers that 
seven pages of often arcane legal language could be streamlined 
into a three-page document in plain English, understandable to 
malaria researchers worldwide.
Once the terms of submission were published, it became clear that 
access to data submitted to the WWARN database was restricted 
to the group submitting the particular dataset and to WWARN 
employees, who would only share the aggregated results of any 
analyses they performed. The earliest Terms of Submission added: 
“In the event that WWARN receives a request to contribute data to 
an external project or collaborative analysis, it will not contribute or 
grant access to your data without your express permission.”
Despite these restrictions, many interviewees, including several who 
did eventually contribute data to WWARN, were initially reluctant 
to provide research results to the database. By far the most common 
reason given, especially among respondents from malaria-endemic 
countries, was the fear that WWARN researchers based at Oxford 
or other well-resourced universities would analyse their data and 
publish results before they themselves had time to get out of the 
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clinic and write up their findings. Though all interviewees (includ-
ing those who chose not to share data with WWARN) recognised 
the contribution that data sharing might make to global surveillance 
of malaria resistance, most were not initially prepared to risk being 
“scooped”, thus sacrificing personal, first-author publications and 
the chance for academic advancement.
“If you’ve shared the data there’s a feeling that, well, you never get 
it back… You feel like you have lost something. It’s a global good, 
everyone is seeing that, but you’ve lost it as the person who got the 
study going.” 
(I19, Endemic country researcher, data contributor)
Others chose not to contribute data at all, because WWARN did not 
pay for data collection. The network did develop and share data col-
lection and analysis tools, and provided some funding for training 
in analysis and other capacity building activities, but some felt the 
“carrot” was simply not big enough.
“Where do they expect me to get the resources to go and conduct 
prospective studies? You can’t expect me to hand my data to you 
if you didn’t even support me to collect it […]. If I know you have 
21 million dollars and you say all you can do for me is invite me 
to put it in some database and then show me how to do some meta- 
analysis, well, I’m not impressed.
(I20, Endemic country researcher - not data contributor)
Researchers were also concerned that the curation process might 
reveal weaknesses in the data, potentially calling into question 
published analyses. Interviewees in industry were most worried 
that re-analysis might yield results that differed slightly from 
those used in product registration, while some policy-makers had 
concerns over data ownership.
“For the national programmes, the question of data ownership is 
very real. More than once I’ve heard people say: why are we giving 
African data to England? So you still need a lot of discussions with 
countries, so that they don’t think their data are being “stolen” by 
the north.”
(I9, Former WWARN employee)
The WHO, the most important bridge between national programmes 
and the wider research community, could perhaps have helped in 
those discussions. The global body wrote several letters support-
ing the idea of the network, and several WHO experts, including 
those responsible for malaria resistance surveillance, contributed 
to the planning and development of WWARN. The arrangement 
highlighted the extent to which WHO relied on “soft” money, such 
as grants from BMGF and other donors, to carry out its normative 
functions.
“In the malaria department like all the disease specific ones, 
the Member States provide less than 20 % of the budget. [The 
department] has to go out getting money, so [is] not so different 
from academic institutions. But [the WHO has] all the limitations 
of having to answer to all of [the] Member States, to follow all the 
protocols and regulations, to conform with other UN institutions.”
(I07, Global health organisation employee)
The 2009 memorandum of understanding between WHO and 
WWARN was not enough to reassure technical experts within 
WHO. They had been working for many years to support 
surveillance of malaria treatment failure on a shoestring budget, 
and they felt undermined by the surge of resources available to 
WWARN.
“When [WWARN] started to get lots of money[…] they started to 
think they could duplicate WHO work, normative and surveillance, 
and progressively replace this activity in WHO, take it over and run 
it on their own.” 
(I01, Global health organisation employee)
Virtually all interviewees said that the relationship between the two 
organisations was scarred as a result of these rivalries. The tension 
passed down to WHO country offices, which work closely with 
national malaria control programmes. According to a senior malaria 
adviser to several health ministries:
“It is true that WHO also influenced NMCPs [national malaria 
control programmes] not to share the data.” 
(I17, Global health organisation employee)
Technical issues in data sharing. Important technical decisions had 
to be made in the design and construction of the database. Many 
of these significantly affected the pace at which the collaboration 
proceeded.
Interviewees described the following debates:
1. Pre-definition of the purpose and end-use of the database 
Data scientists and informatics staff favoured a clear description 
of the end-use of the database at the design stage; malaria scien-
tists, wishing to maximise the possible uses of this as yet untested 
resource, preferred to avoid any definition that would foreclose pos-
sible future uses. They advocated maximum flexibility, and resisted 
a tight, purpose-driven design.
2. Heterogeneity of data types 
By design, WWARN intended to include clinical, in vitro, molec-
ular, pharmacological and (later) drug quality data. The most 
heterogeneous of these were the clinical data. The variables 
defined by the WHO’s resistance monitoring protocols, which were 
already standardised, formed the core. However there was 
considerable debate about which other data should be included. 
For other variables, such as in vitro, different research groups were 
measuring similar indicators using different methods or defini-
tions. At the time, no agreed standards existed and they needed to 
be developed (something that has since been achieved, as noted 
below).
3. Heterogeneity of data formats 
WWARN aimed to bring together information from many individ-
ual research groups, each of which stored their data in different file 
formats or using different metadata, even for indicators measured in 
the same way. Some data scientists, notably those with experience 
building genomics databases in which free sequencing had been 
offered to data contributors, advocated requiring data contributors 
to standardise data formats before submission. Others felt that this 
would discourage the contribution of clinical data (which tends 
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to be more complex than genomic data), especially in a setting 
where database managers could not offer free sequencing or other 
similarly attractive incentives in return.
4. Inclusion of retrospective data 
Information scientists noted that retrospective data tend to be 
more varied in content and format than data gathered with shar-
ing in mind, while also being ill-suited to meeting the original goal 
of the database, which was to allow for real-time surveillance of 
resistance. Malaria scientists, on the other hand, thought exclud-
ing retrospective data would restrict the value of the resource. In 
addition, few researchers were prepared to contribute prospective, 
prepublication data; without retrospective data it would be hard 
to arrive at a proof-of-concept.
5. Terms of submission 
Terms of submission and use seek to clarify the rights and respon-
sibilities of data contributors and of secondary analysts. More 
restrictive terms of use, for example the obligation to seek the 
express permission of the contributor for every re-use of the data, 
tend to reassure contributors, while increasing the workload of data 
managers. While some interviewees (principally in global health 
organisations) were philosophically in favour of open access to 
data, most acknowledged that more restrictive conditions might be 
necessary to promote sharing in an environment in which sharing 
was virtually unknown.
6. Curation on submission or on demand 
The more heterogeneous the data, the greater the burden of 
curation - of checking data validity, completeness and consist-
ency. This raised the question of whether all variables in a dataset 
should be curated at the time of contribution, or whether data 
should be ingested but some of the curation work should be post-
poned until demand arose for a particular variable to be used in 
analysis.
Table 2 summarises the choices that data scientists were faced 
with when setting up the WWARN database; the grey rows 
indicate the choices that the network ultimately made. As the 
table shows, WWARN in most cases chose options that would 
maximise the likelihood that researchers would contribute data, as 
well as allowing for the greatest possible range of uses of data in 
secondary analysis. The options that delivered the most complete, 
useful database were, however, never the fastest or the cheapest.
This meant that progress in constructing the database was inevita-
bly rather slow, which came as little surprise to interviewees who 
had been involved in similar projects in different fields:
“At [an HIV data sharing consortium] it took us a good seven years 
to build relationships, to get people to want to contribute their data, 
and this was, like, 18 guys who already knew each other.” 
(I03, Former WWARN employee)
However, the time invested in the relationships and structures 
needed to build a secure and useful data platform led to some 
frustration on the part of global health bodies who had hoped 
that data sharing would yield quick insights into antimalarial 
resistance.
“WWARN was running for three years and there was no product; 
from a funder’s point of view it’s understandable that people say 
‘OK, you’re not delivering’”. 
(136, Current WWARN employee)
Table 2. Design issues considered when setting up individual patient databases. PD: 
Purpose-dependent. Fields shaded in grey indicate WWARN’s choice.
Issue Choice Minimises Maximises
Cost Time Data 
contribution
Research 
Utility
End Use
Clearly pre-defined ✓ ✓
Flexible design ✓
Heterogeneity of 
data type
Homogenous ✓ ✓
Heterogeneous ✓ ✓
Heterogeneity of 
data format
Standardised before intake ✓ ✓
Standardised after intake ✓
Age of data
Prospective only ✓ ✓ PD
Retrospective data also 
included ✓ PD
Terms of 
submission
More open ✓ ✓ ✓
More restrictive ✓
Time of curation
On demand* ✓ ✓
At intake ?
*WWARN’s practices on curation vary - core variables are curated at intake, others, often those used for Study 
Group analyses described below, on demand.
Page 8 of 22
Wellcome Open Research 2017, 2:63 Last updated: 03 OCT 2017
These choices, and the standards-setting and tools development 
that flowed from them, were especially time-consuming for the 
network’s largely unpaid science groups heads and other senior 
malaria specialists.
“There are people who put in months of time, including my time, it 
was a massive sink of time.” 
(I12, WWARN science group head)
WWARN refocuses the scientific collaboration
Table 3 provides a timeline, derived from the records review, 
of milestones in WWARN’s development. Interviewees were 
unanimous in saying that by mid-2010, it had become apparent 
that WWARN was unlikely to develop successfully into a real- 
time surveillance tool that would be used by national programmes. 
The database was functional, and included 25,000 patient records 
from 78 studies, 64 of them provided by just three research 
groups who were enthusiastic supporters of the WWARN 
project. The longer-than-expected design phase had combined 
with professional disincentives and institutional and personal 
rivalries to create barriers to expansion that were simply too high 
to overcome.
In the meantime, however, the network had made solid (if not 
yet highly visible) progress developing key data management 
tools, governance structures and relationships with researchers 
in endemic settings. Rather than waste this important work, the 
network changed tack, focusing on academic research rather than 
real-time tracking of resistance.
The study group model. WWARN science group heads and staff 
members began to formulate specific scientific questions that 
Table 3. WWARN Timeline, derived from records review. DP: dihydroartemisinin-piperaquine; AS-AQ: artesunate –amodiaquine; AL: 
artemether-lumefantrine; WHO/TDR: The World Health Organization/Special Programme for Research and Training in Tropical Diseases.
Date Events
2004 – 2007 Carol Sibley first presents the idea of WWARN at the 1
st Molecular Approaches to Malaria meeting, 2004. 
Side-meetings continued at many malaria/tropical medicine conferences.
September 2007 Seattle Biomedical Research Institute awarded US$1,021,401 by the Bill and Melinda Gates Foundation to begin planning WWARN.
November 2007 WWARN concept launched at the annual meeting of the American Society of Tropical Medicine and Hygiene.
2008 Oxford University chosen as a location. 
Philippe Guerin chosen as Executive Director.
January 2009 Oxford University awarded US$20,674,222 grant from Bill and Melinda Gates Foundation to implement WWARN.
July 2009 Memorandum of Understanding with WHO.
July 2009 WHO awarded US$7,828,470 grant from the Bill and Melinda Gates Foundation to support for therapeutic efficacy surveillance studies.
2009
United States Agency for International Development grant received by Molecular Group in collaboration with 
University of Maryland for training of researchers in Southeast Asia. 
Data Sharing Agreement drafted.
2010 Development of data sharing software. 
Consensus meeting held with WHO.
March 2011 Terms of Submission document finalised.
July 2011 Memorandum of Understanding with GlaxoSmithKline.
October 2011
First study groups launched: 
DP Dose Impact 
AS-AQ/AL Molecular Marker 
AS-AQ Dose Impact
November 2013 First study group paper published.
October 2013 Grant from ExxonMobil.
2014
230 partners working with WWARN. 
100,000 individual patient data from 50 endemic countries. 
Novartis requested use of the Parasite Clearance Estimator model developed by WWARN to register new drugs. 
Agreement to standardise data collection on core variables, along with flexibility to collect additional variables.
2015 Change in board structure and membership. 
Board approval for development of other disease platforms.
2016 Provisional agreement with WHO/TDR to develop independent data access committee. 
Launch of the Infectious Diseases Data Observatory initiative.
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could not be answered by a single clinical trial, forming multi-site 
study groups. The first study group conducted a pooled analysis 
of lumefantrine pharmacokinetics in patients with malaria. The 
senior authors of 31 publications were asked to contribute specific 
variables to the WWARN database to answer a specific ques-
tion. They were invited to collaborate in the analysis, and assured 
of authorship on any resulting publication. Twenty-six research 
groups shared their data with WWARN for the study.
“Suddenly, eighty percent of people wanted to be part of something 
they couldn’t do on their own, because they saw the real value 
there.” 
(I04, WWARN science group head)
The early ‘study group phase’ acted as a proof-of-concept for data 
contributors and for users alike. As more pooled analyses were 
published, apparently without the damage to careers that endemic 
country researchers first feared, data managers said they saw con-
tributions to the database increase.
“People now say yes to study groups much more quickly than they 
did in the beginning. The DP [Dihydroartemisinin-Piperaquine] 
study group was two and a half years from first call going out to 
publication. The gametocyte study group was 12 months.” 
(I45, Current WWARN employee)
By mid-2016, the database had grown more than five-fold in terms 
of patient records. It now included 186 clinical trials comprising 
over 135,000 individual patient records. This included a remark-
able 80% of all published clinical trials reporting on the efficacy 
of artemisinin combination therapies. In addition, the database 
contained 103 molecular studies. Data are contributed by academic 
groups, pharmaceutical companies and non-profit drug develop-
ment groups such as Drugs for Neglected Diseases Initiative, as 
well as non-governmental organisations such as Mèdecins Sans 
Frontières.
By July 2016, 18 “core” papers using data from the WWARN 
database had been published, mostly developing new methods 
or addressing questions that could only be answered by com-
bining data from large numbers of studies. At least two of these 
papers contributed directly to a change in WHO treatment 
recommendations25. The WWARN website lists another 59 papers 
by researchers who have collaborated with the network. Table 4 
provides information about the content of these papers; 
all references can be downloaded using the bibliography file at 
doi: 10.7910/DVN/V1TKIO20). Papers considered core WWARN 
analyses are tagged “wwarn_core”.
Creating equity. Clinical trials related to malaria usually occur 
in malaria-endemic countries, and most are led by researchers 
from those countries, sometimes in partnership with research 
institutes in non-endemic countries. WWARN’s early scientific 
directors were based at well-resourced universities in Seattle, 
Baltimore, Paris, Darwin, Oxford and Cape Town. The WWARN 
database is hosted by Oxford University in a secure cloud-based 
environment. Two interviewees external to WWARN mentioned 
that users physically located outside of Oxford who hoped to 
analyse pooled data remotely faced access restrictions. From the 
start, the network recognised that establishing equity would be a 
challenge, but should be prioritised.
“You can’t simply ignore the disparity between the resources in the 
north and south. If you try and bury that in the sand at the start, it 
will stop the project from working.” 
(I09, Former WWARN employee)
WWARN was not intended as a research funder, and did not 
provide funds to carry out field research. Rather, the network 
supported researchers from malaria-endemic countries by 
developing standardised clinical protocols and microscopy and 
other procedural guidelines. These were followed with analytic 
tools such as the parasite clearance estimator. Interviewees said 
the tools were intended to reduce duplication of effort and increase 
efficiency. The tools also helped researchers to collect data in 
standard formats that would contribute to quality, and that could be 
easily ingested into the database and analysed.
“We realised in [2010] that if you didn’t provide measurement 
tools then people would measure things in different ways. So we 
started the idea of the parasite clearance estimator, because it was 
necessary to have a standardised way of measuring artemisinin 
resistance. We realised there was a bit of anarchy in the in vitro 
testing, so let’s get a standardised measure for that... It was all very 
well having data, but what if they are wrong? Capacity building is 
not touchy-feely, it’s necessary.” 
(I34, WWARN board member)
Table 4. Content Analysis of WWARN papers. RCT: 
randomised controlled trial.
Type of paper Core WWARN Other Total
Pooled analysis 8 0 8
Traditional meta-analysis 0 5 5
Systematic Review 1 3 4
Opinion piece or discussion 
article 2 18 20
RCT report or protocol 0 3 3
Other epidemiological 
study 1 10 11
Molecular, in-vitro or 
pharmacokinetic study 3 7 10
Modelling study 1 3 4
Methods study 2 3 5
Evaluation of equipment 0 1 1
Medicine quality 0 3 3
Other 0 3 3
18 59 77
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The 2009 grant application clearly described capacity building 
efforts that would help to support endemic-country researchers 
in using these tools and in analysing their data, using a regional 
centres of excellence model. Although the Foundation awarded the 
grant, its staff said they had misgivings about the approach early 
on.
“I remember… being very concerned that this was going to be an 
increasingly expensive undertaking if we had regional, sub-regional 
centres. Because there seemed to be rapid growth in WWARN, in 
terms of its footprint, the number of people it had.” 
(W21, Former BMGF employee)
Several interviewees, including current and former WWARN 
staff, science group heads and current or former employees of 
global health organisations, including BMGF staff, said that the 
Foundation was strongly focused on efficient delivery of outputs, 
and never fully supported capacity building efforts.
“We had concerns about WWARN trying to develop a fairly large 
footprint. It wasn’t clear how that was going to benefit what we 
were trying to do… The Gates Foundation has been at best ambiva-
lent about supporting capacity to undertake the studies in endemic 
countries. It hasn’t been part of the Foundation’s objective. … When 
someone in the Foundation makes an investment, they are expected 
to deliver. When the deliverable is data and information generated 
in a defined timeframe, you make your bet where you’re likely to get 
the most yield. And that’s very likely to be a known investigator and 
a known institution.” 
(I27, Global health organisation employee)
Staff who worked for the Foundation also said during the witness 
seminar that at the time that the original WWARN grant was made, 
BMGF procedures made it very difficult to channel money directly 
to endemic-country institutions which were collecting data. Project 
completion reports indicate that funding for most regional offices 
and other capacity building activities was terminated in 2013, at the 
insistence of BMGF.
While channelling funds to institutions in non-endemic countries 
heightened existing inequities in the eyes of some endemic 
country researchers (see quote from interviewee I20, above), others 
saw an opportunity in the desire of scientists from non-endemic 
countries to access the data they collected in their clinics.
“What we have seen is that when we have data, some of the data 
we don’t even think have value, [it] may have very great value to 
other institutions. Then you can negotiate and can get a good place 
on the author listing.” 
(I13, Endemic country researcher - data contributor)
However this researcher and several others expressed concerns 
that without more exposure to global datasets and training in com-
plex meta-analysis, scientists from non-endemic countries would 
be unable to join the “big data” era. They would be increasingly 
consigned to the data collection end of the research spectrum, their 
involvement in analytic collaborations such as study groups merely 
tokenistic. Researchers from wealthy countries, for their part, said 
that strenuous efforts to involve endemic country colleagues in 
analysis were often frustrated because those researchers who had 
the capacity to contribute rarely had the time to do so.
“They come back from Europe with their PhD, and they get made 
head of some institute for medical research, and that essentially 
ends their research careers.” 
(125, WWARN science group head)
Table 5 shows the distribution of authorship across WWARN-
related papers published by July 2016. The 18 “core” papers are 
those based on analysis of data drawn from the WWARN data-
base; the remainder are the other papers listed on the “Impact” 
page of WWARN’s website. These data reflect the fact that the 
majority of study groups have been initiated by science group 
heads or WWARN, who do the bulk of the analytic work.
The seven papers ‘authored’ by study groups list a mean of 116 
contributors alphabetically at the end of the paper (range 44–196). 
The list includes those who contributed data; also undifferentiated 
in the list are those who conceived the hypothesis, ran the analysis 
and wrote the paper.
Several interviewees, covering all groups and including WWARN 
board members and staff, were concerned that the network, 
whose scientific group heads are spread across four continents, 
would be perceived as an “Oxford data grab” because of the 
affiliation of the secretariat. We therefore also looked at the insti-
tutional affiliations of first and last authors. Of the 11 “core” 
papers not authored by groups, 10 listed first authors with Oxford 
University affiliations (often in conjunction with those of other 
institutions), and 9 of the last authors were also from Oxford. 
Table 5. National origin of authors on WWARN-associated 
publications.
Core WWARN 
papers (N=18)
Other papers 
(N=59)
WWARN study group 7 0
Endemic country 1st author 3 13
Non-endemic country 1st 
author 8 46*
Endemic country last author 0** 4
Non-endemic country last 
author 11 50
Both 1st & last authors from 
endemic country 0 2
Both 1st & last authors from 
non-endemic country 11 52
*Includes 5 single author papers
**One study group paper additionally includes 9 named authors. The 
named authors are listed alphabetically and we have thus excluded the 
final (endemic country) author from this count.
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Of the other 59 papers, 29 had an Oxford-affiliated first author 
and 28 an Oxford-affiliated last author. For 17 of the 59 papers, 
neither first nor last author was affiliated with the university where 
the database is housed.
A spreadsheet listing all the papers and giving details of the 
number of authors per paper, citation counts and affiliations of 
first and last authors can be downloaded at doi: 10.7910/DVN/
V1TKIO20.
Involvement in formulating research questions. In recent years, a 
small number of researchers in some universities in non-endemic 
countries have requested data for pooled analyses from WWARN, 
sometimes to answer questions of immediate interest to industry 
or global health organisations. However study group questions 
are rarely initiated by researchers from malaria-endemic countries 
other than South Africa.
Many interviewees expressed a generalised concern that the quality 
as well as the relevance of analysis could suffer because platforms 
such as WWARN enabled analysts who had no involvement in data 
collection to ask potentially irrelevant questions and to interrogate 
data without fully understanding its provenance. They underlined 
that this is an issue not limited to WWARN or the field of malaria, 
but rather, reflective of a broader structural weakness in global 
health research.
“I have the feeling lately that there is a growing gap between all the 
brains and data crunchers in the high income countries, then the 
data collection is in the field.... All the biases are not even imagined, 
so data are being crunched a bit blindly, giving results that aren’t 
really reliable in the end. We need more of a link between those two 
worlds”
(I35, Former WWARN employee)
The feeling of being excluded by an overly global research agenda 
expressed by the endemic country policy-maker quoted earlier 
(under “Meeting different needs”, I28) was shared by some endemic 
country researchers.
“You need to empower people to ask questions not just relevant 
to WWARN, but questions that are relevant to themselves to start 
with and to their immediate environment. WWARN is looking from 
outside; some people who are in the field every day are seeing 
issues, and they want to answer those questions. If you feel that they 
don’t care about your questions, well, you don’t feel encouraged.”
(I20, Endemic country researcher - not data contributor)
On the other hand, some policy-makers simply have limited 
experience of or interest in the science of the disease they are 
charged with overseeing, according to one interviewee who has 
worked closely with several national malaria programmes.
“Someone comes in [as malaria programme head] for a couple 
of years - without even having to know a malaria life cycle - in 
order to step up to a higher position… At the same time for malaria 
programme staff, usually there is no incentive for research involve-
ment. Some have an interest in operational research, but often, they 
just want to know what the findings and interpretations are.” 
(I17, Global health organisation employee)
The future: adapting, accelerating, reproducing
The early efforts put into tools creation and data curation 
increased the volume of data available and the speed at which 
newly contributed data can be added to the database. In mid-2016, 
the WWARN board began to discuss changes to the terms of sub-
mission that would allow researchers to grant access to their data 
in perpetuity if they chose, rather than be recontacted for every 
use. Access requests would be considered by an independent 
Data Access Committee. This committee was constituted under 
the auspices of the WHO’s Special Programme for Research and 
Training in Tropical Diseases (TDR) in April 2017, after data 
collection for this study ended26.
Some feel this does not go far enough towards making data reuse a 
default option.
“We have to change the conversation to: data sharing is a given. 
If you don’t want to share you have to take action yourself to opt 
out, instead of putting the onus onto people to make sharing hap-
pen. If we did it the other way around, people would quickly find 
data sharing is not as bad as they thought and we’d make progress 
much faster.” 
(I43, Global health organisation employee)
Secondary analysts who have led study groups say it has saved 
them months or years of work seeking permissions and standardis-
ing data.
“People have done so much work to collect the data, then WWARN 
works hard to standardise it; we just sweep in at the end and get this 
lovely clean data to work with, it’s very easy for us.” 
(I14, Secondary analyst)
However their experience highlights the importance of data 
discoverability: an informatics issue that was not considered by 
WWARN’s designers in the initial phase, when it was assumed 
that access for external users would be limited to the summary data 
shown on the WWARN Explorer. Discoverability - the ability of 
potential outside users to find the data set and easily understand 
what it contains - is critical if the data are to be reused by any 
investigator with a legitimate research question that may be 
addressed by data held in the resource. WWARN took care to 
develop data management tools that included a full audit trail 
for the variables that they standardised. However, it was not 
feasible to fully curate all of the variables that were not related to 
antimalarial efficacy, thus limiting the ability of potential users 
of the resource to discover and request access to variables of 
interest. A comprehensive data inventory and a data dictionary, 
including of as yet unused variables, is currently being developed.
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Adapting the WWARN model for other diseases in a new era. 
Many interviewees in global health organisations and industry, 
including some initially sceptical about WWARN, feel that the 
standards to which WWARN has contributed will benefit the 
research community more broadly. They noted, for example, 
the work done by WWARN collaborators to develop malaria 
standards for use by the Clinical Data Interchange Standards 
Consortium (CDISC). From 2017, CDISC metadata standards 
must be used for all data submitted to United States Food and 
Drug Administration by organisations seeking to register drugs 
and medical products; other regulators are expected to follow suit. 
As more users converge around the standards, the interoperability 
of data will increase and curation costs will fall.
“The tools linked to the CDISC standards, that’s all done, so let’s 
not re-do it. That really would be stupid.” 
(I16, Global health organisation employee)
The interviewee went on to note that data governance structures 
developed by the network have also proven robust to the needs of 
pooled analyses.
“The legal framework is an essential piece that we can’t underesti-
mate. The right to use the data, how the data are curated, how can 
they be published, all these aspects, it’s a very sensitive question, 
and I trust that WWARN has already gone through a lot of problem 
solving.” 
(I16, Global health organisation employee)
Several interviewees warned that the WWARN model, and the 
institutional structures in which the network is embedded in a uni-
versity, may not be suitable for all diseases, or all uses. The study 
group model depends on an academic publication incentive which 
has little value for researchers working in government or medi-
cal charities, and which is inimical to the needs of surveillance. 
However, most interviewees were confident that the structures 
and tools developed by WWARN for malaria could and should be 
used as building blocks for shared clinical data platforms for other 
diseases of poverty.
Since the case study was undertaken, WWARN has formally 
launched an umbrella organisation, the Infectious Diseases 
Data Observatory, to facilitate this process. At the invitation of 
research communities working on clinical efficacy studies in 
other neglected tropical diseases, the team has already begun 
to adapt the data infrastructure, informatics tools, policies and 
procedures for other diseases; these efforts demonstrate the time 
and cost savings achieved by building on the WWARN experience.
“Some of the tools we’ve developed are pretty powerful now, 
and we’re also proving that they can be adapted relatively quickly, 
compared with the original development of them, to other diseases. 
So for instance last summer [2015] we did a pilot to develop a 
schistosomiasis data sharing platform, and I’d say that was pretty 
well advanced in just three or four months, from scratch.” 
(I45, WWARN employee)
WWARN managers said the development of functional pilot 
platforms for schistosomiasis, Ebola and visceral leishmaniasis 
has cost a great deal less than the original malaria platform. Costs 
vary with the volume of data and the complexity of the disease 
– Ebola, for example, requires data from anonymised patients to 
be linked over time; this had led to considerable modifications 
in both data structure and governance mechanisms. In general, 
however, set-up costs range from US$ 100,000 to US$ 900,000. 
These costs cover development of the data infrastructure and 
governance mechanisms, but do not include investment in 
extensive consultation among potential contributors or users, or 
support for research or surveillance communities to generate or 
analyse data, nor the on-going costs of platform management. 
An very important cost that tends to be neglected when budget-
ing for data platform development is the prodigious amount of 
time and expertise contributed by researchers themselves. In 
the case of WWARN, much of this was a pro-bono contribution 
made by dedicated malaria specialists with established (and 
securely-funded) careers.
“We need to distinguish how [the WWARN model] works in rela-
tion to the contributors, but also in relation to very different disease 
questions. Infectious disease epidemiology is very different from the 
efficacy of chemotherapy... On top of all the money that has been 
spent [on WWARN], there is a lot of high quality input in time, com-
pletely unpaid... For other diseases we don’t have that.” 
(I22, WWARN board member)
Many respondents noted that changes in community norms regard-
ing data sharing relating to diseases of poverty, in part a response 
to pressure from funders, would reduce the high costs of consensus 
building that WWARN faced in its early years.
“The fact that [WWARN] has standardised data so that everyone 
can learn and analyse with the same tools: that is going to be the 
future, however much people are conservative and reject it and are 
afraid of it. This will happen, so let’s make it useful.” 
(I16, Global health organisation employee)
Discussion
Our case study aimed to capture learning about data sharing 
from the experience of WWARN, a pioneering data sharing 
initiative, launched at a time when hostility to the practice was 
entrenched. Box 1 summarises the characteristics of a data 
sharing platform that has the potential to increase policy-relevant 
knowledge.
Page 13 of 22
Wellcome Open Research 2017, 2:63 Last updated: 03 OCT 2017
Box 1: Key lessons from the WWARN experience
For a data sharing platform to contribute to longer, healthier 
lives:
People who collect data must be incentivised to share it
The “greater good” argument may work with some people, such 
as those who work for NGOs and some governments. Where 
sharing data conflicts with personal or institutional incentives 
(for example by potentially undermining product registration by 
pharmaceutical companies or career progression for academics, 
or by exposing data quality issues) it will be resisted. Promoters 
of data sharing should work to change institutional incentives in 
ways that support sharing.
Structural inequities in science must be reduced
Useful data sharing may depend on local knowledge, and 
local knowledge must thus be actively incorporated into shared 
datasets, question setting and analysis. In many parts of the 
world with high burdens of disease, that local knowledge is 
produced by research systems that suffer from decades of 
under-investment. Unless the resulting imbalance in scientific 
capital is actively addressed, data sharing initiatives are likely to 
produce analyses of limited relevance for policy-makers in many 
areas.
There must be a clear demand for the data
Each potential user community must articulate its own needs. 
Academic researchers and research funders should avoid 
making assumptions about what policy makers want and need. 
A successful platform meets expressed needs.
Relationships with key “gatekeepers” must be productive
The global health landscape is institutionally complex: progress 
often depends on cooperative action by groups with different 
and sometimes competing interests. Particular actors (often 
funders or global bureaucracies) can determine whether 
research gets done, or its results get used, thus affecting the 
potential scope and likely utility of a data sharing platform.
Investment in data curation and governance is essential and 
often substantial
Data standardisation is essential for pooled analyses; key 
informatics decisions will determine how long it takes and how 
much it costs, but the costs will always been front-loaded. 
Standardisation tools as well as governance mechanisms can 
be amortised across time and platforms as tools and systems 
are adapted or replicated. Investors must plan for high start-up 
costs and, because secure and persistent data storage is also 
needed, for long term support.
Researchers should plan for sharing, thus reducing costs
The use of shared protocols, measurement tools and metadata 
standards greatly reduces the burden of data standardisation. 
While researchers should not lose sight of local specificities, 
standardising core data collection tools at the outset will make 
data sharing cheaper, easier and more productive.
Governance must be transparent, equitable and flexible
Clear, concise terms of data submission and use can help erode 
the fear many researchers still have of sharing data. While more 
restrictive measures may be necessary to build trust, flexible 
terms should allow greater sharing as experience grows and 
norms change.
WWARN founders envisaged a “comprehensive efficacy and 
resistance database [which] will provide malaria control manag-
ers, surveillance programs and policymakers with prompt access 
to up-to-date evidence of temporal and geographic trends in 
antimalarial drug resistance at the global scale24”. We found that 
the institutional and professional incentives prevailing at the 
time made it impossible to achieve this goal. However, once the 
Network aligned its practices with prevailing incentives, it proved 
both the feasibility of compiling and standardising individual 
patient and parasite data across hundreds of studies, and the 
utility of pooled analyses in guiding treatment policy.
The hurdles WWARN initially faced were the product of archaic 
academic norms, coupled with a dysfunctional global health 
architecture. On the ‘supply’ side, academic researchers were 
unwilling to risk sacrificing publications (and thus promotions) 
by providing pre-publication data. Government researchers did 
not supply data in deference to WHO officials, who were unsup-
portive because they were concerned that the venture duplicated 
their own work. On the ‘demand’ side, the academic researchers 
who conceived of the platform made assumptions about policy- 
makers’ needs, without actually consulting them widely. In a 
‘pivot’ similar to those performed by many successful ventures in 
the information technology sector27,28, WWARN then reformulated 
its goals, aligning them to the prevailing incentives while side- 
stepping institutional obstacles. Rather than focusing on the 
active surveillance of antimalarial resistance, the Network turned 
its attention to generating new learning from pooled analy-
ses – arguably a goal with more immediate value for millions of 
patients around the world. In the course of developing this more 
research-centred platform, WWARN has developed many systems, 
tools and procedures that can be extended to platforms aggregating 
individual patient data for other diseases. Indeed, that process has 
begun.
The WWARN experience underlines the extent to which cur-
rent incentives in academia run counter to the open sharing of 
  Informatics systems, tools and governance structures can 
be shared
WWARN has developed good systems for the automated ingest 
and management of heterogeneous malaria data; community 
meta-data standards and systems for developing them; and 
clear governance structures. All of these can be adapted 
for other diseases. It’s important, however, to reconsider the 
purpose and users of the new platform. Governance structures 
designed for platforms supporting pooled analysis of post-
publication data by academics will not serve the needs of 
platforms aiming to provide real-time surveillance data.
Disease expertise remains necessary
While much can be shared across platforms, deep knowledge of 
specific disease fields is necessary at the platform design stage, 
as well as to guide useful analysis.
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information. In theory, pooling data from large numbers of similar 
clinical trials provides an opportunity to unearth new knowledge 
more rapidly, and several consortia and closed research collabora-
tions stand as proof-of-concept of the utility of sharing data col-
lected in low-income settings16,29,30. Like many other collaborations, 
WWARN was able to attract contributors only after it committed 
to a model that allowed contributors to restrict access to their data, 
and rewarded them with authorship on publications likely to be 
highly cited. By adopting the study group model, which appealed 
to data contributors, WWARN was able simultaneously to build up 
the database and to begin to conduct important pooled analyses that 
have contributed directly to improvements in global policy.
Broader consultation in the planning stages of WWARN may have 
revealed as somewhat unrealistic the initial goal of short-circuiting 
cumbersome publication processes to get actionable data into the 
scientific commons more rapidly. However, the network should be 
applauded for changing its strategy; WWARN was in no position by 
itself to change the personal and institutional incentives that stand 
as obstacles to the true potential of data sharing. If that potential is 
to be achieved, the publication of papers in peer reviewed journals 
must lose their pre-eminence as a measure of scientific productiv-
ity in academia. We believe that depositing data in well-curated, 
quality-assured databases should be rewarded professionally just as 
publication of papers in high impact journals now is. The use of 
data in a pooled analysis that demonstrably changes policy should 
be rewarded at least as well as a citation in a journal. Outside of 
academia, there is a need to reform the institutional relationships 
and funding mechanisms that create rivalry and open competition 
between organisations who at least nominally share the goal of 
increasing the flow of high quality scientific evidence, and reducing 
disease and death.
Once it bowed to the prevailing incentive structures, the WWARN 
network published several pooled analyses which established the 
value of the resource as a source of additional learning. This has 
encouraged drug developers and global health organisations to 
begin to request analyses using the database, and has prompted 
changes to access policies to facilitate use of the resource by all 
legitimate analysts.
Most of the proposed analyses seek to inform policies which will 
be made at the global level. Global policies do often trickle down 
into country-level policy because health ministries in lower-income 
countries follow global guidance quite closely. For two decades, 
investigators have pointed out that those setting the questions in 
health research in tropical countries are very rarely natives of those 
countries, and almost never the people who could use research 
results to effect change31–33. Several interviewees in our study were 
active as both researchers and policy advisors; they tended to use 
international studies to bolster local findings which politicians find 
more immediately compelling. Where the divide between research-
ers and policymakers is more pronounced, our findings support 
the view that agenda-setting in global health research remains lop-
sided, even in the context of a project that set out to be an inter-
national collaboration. One potential way of increasing the local 
utility and uptake of data would be to encourage more active par-
ticipation in question-setting by national programmes, working 
together with the endemic country researchers who best understand 
the local realities.
However this may be hard to achieve in reality. National policy 
makers were under-represented in our study, in part because their 
close relationship with WHO has in many cases stood between 
them and direct contact with WWARN. The policy makers we 
spoke to stressed that they were consumed with day-to-day pro-
gramme delivery. This was confirmed by several endemic country 
researchers who serve on national advisory panels; they noted that 
national programme managers had little band-width left for formu-
lating research questions that did not relate directly to operations. In 
addition, policy makers were wary of pooled analyses, feeling that 
they were likely to obscure local realities.
Endemic-country investigators said they lacked the skills and the 
resources to initiate study groups themselves; with the exception 
of South Africans, few researchers from endemic countries have 
yet initiated an interrogation of the shared dataset. This mirrors 
the experience reported by the Alpha Network, a large consortium 
of HIV researchers which invests more heavily than WWARN in 
local skills-building35. Between 2005 and 2015, Alpha held a dozen 
multi-country analysis workshops in various sub-Saharan African 
countries, each focused on a specific research question. An exami-
nation of the workshop descriptions on the Alpha website suggests 
that many of the topics are chosen because they are of interest to 
international modelling groups or UNAIDS34. This supports anec-
dotal reports from Alpha network members and from an interviewee 
in our study with experience in a different HIV data sharing consor-
tium, who said that researchers from participating sites have been 
slow to initiate secondary pooled analysis of potential relevance to 
local policy-makers.
This raises the possibility that large, pooled, multi-country data-
sets are of limited immediate value to national disease control 
programmes; the information they yield is likely to affect local 
programmes only through the mediation of higher-order “brokers” 
in global health. These brokers currently include the WHO, other 
global health organisations and well-resourced research groups run 
mostly by universities and other institutions in rich countries. In 
theory, there is no reason that endemic-country researchers should 
not share or take over the complex pooled analyses that fulfil the 
needs of these information brokers. Indeed, their superior under-
standing of the contexts in which data were collected and policies 
must be implemented mean they are well-suited to the task. How-
ever our study suggests that in most endemic countries, well-trained 
researchers are principally rewarded for collecting and analysing 
primary data. They felt that they - and many of their peers in low-
income countries - lacked full access to the collaborative networks 
and technical skills that large pooled analyses require. Initiatives 
such as the INDEPTH network, which builds capacity for data 
management, sharing and analysis across demographic surveil-
lance sites in 19 countries in Africa, Asia and Oceania, demonstrate 
how investment in data sciences can pay off. Targeted calls and 
prizes could provide further motivation36,37, but supporters of 
research may need to earmark a percentage of all funding for 
capacity building if they wish to redress structural imbalances in 
biomedical knowledge generation and use.
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We recommend exploring this dynamic empirically, by actively 
incentivising locally-led, policy-relevant secondary analysis using 
data from WWARN and other similar resources, then systemati-
cally tracking the use of any research results in local policy for-
mulation.
Sharing data with a view to generating new, actionable informa-
tion through pooled analyses requires investment in data curation, 
and in developing workable data governance structures. When 
WWARN took on this challenge they had no model to follow, 
and the investment was very substantial in terms of both time and 
money. This is often the case with pioneering ventures in science. 
Although the effort was of an entirely different order of mag-
nitude, we note that it took 13 years and cost US$2.7 billion to 
arrive at the first draft sequence of the human genome. Structural 
changes to incentives and widespread sharing of methods and tools 
have brought those costs down to under US$1,500 since 200838. 
On a far smaller scale (and with less outside help to change incen-
tives that obstruct sharing), but somewhat analogous nonetheless, 
WWARN’s procedures, informatics tools and policies are now 
being adapted for other diseases far more quickly and cheaply. 
The network has developed a solid foundation on which other 
data sharing infrastructure can be built; research funders and 
other investors in global health have an interest in supporting the 
group to share its experience more widely with other academic 
researchers and beyond.
Our study has several limitations. It was modest in scope, focus-
ing on just one data sharing initiative. Clearly, the experience of a 
single, well-financed group embedded in a well-known academic 
institution, led by passionate scientists dealing with a subject con-
sidered to be of some urgency in global health, will not be relevant 
to all other settings and diseases. No past or present employee or 
close associate of WWARN was involved in data analysis or inter-
pretation for this study, though some had an opportunity to review a 
late draft of the manuscript for accuracy. Employees of the network 
provided access to documentation for the records review, as well as 
suggesting an initial group of people for interview. It is possible that 
this introduced bias to our study. National malaria programme man-
agers are clearly under-represented, for example, in part because 
of the firewall between WWARN and national programmes cre-
ated by the 2009 memorandum of understanding with WHO. How-
ever, we did interview several people who chose not to be involved 
with WWARN as well as several former staff; the range of views 
expressed suggested that we achieved a well-rounded view of the 
network. To comply with the terms of participant consent, and 
because of time constraints, all interviews were coded by a single 
investigator (EP). This forecloses inter-coder validity checks. The 
interpretation of other information, including the records review 
and the witness seminar, was, however, discussed in detail between 
the authors.
The WWARN experience suggests that truly useful data sharing 
platforms must be thought of as long-term, infrastructural invest-
ments; they cannot be thrown up as rapid, project-based responses 
to funder or journal demands. To succeed, a data platform must 
consult widely at the outset with all potential platform users. It must 
align incentives and governance structures to meet the needs of data 
contributors, likely users, platform administrators and funders. If 
it is to maximise its potential impact on health, a platform must 
standardise data and actively facilitate the analysis of pooled data 
to answer locally relevant questions.
Though conceived to generate information about malaria resist-
ance, the true value of WWARN may be in the lessons it has 
provided about the challenges of sharing data in an environment 
where pressure to share still outweighs experience. Key among 
these lessons is that data aggregators do not, by themselves, have 
much influence over the incentives that shape the data sharing 
landscape. It is up to the wider research community - including 
public and private funders, academia, industry and publishers - 
to reshape that landscape so that scientists, physicians and public 
servants are rewarded for sharing data and information towards a 
common goal.
Data availability
Data related to this study can be found in the Harvard Dataverse 
repository, under a CC0 licence, available at doi: 10.7910/DVN/
V1TKIO20.
The files include:
•    Original study protocol with question guide and consent 
forms
•    Completed COREQ checklist for reporting qualitative data
•    Coding tree for NVivo data coding of interviews and docu-
ments
•    Bibliography of WWARN-related papers, in downloadable .ris 
format
•    Spreadsheet of WWARN-related papers with first and last 
authors, institutional affiliations, number of authors, in .tab 
format for download to Excel and other programmes.
The document review included published papers, conference 
presentations and material published by funders or the WWARN 
platform on their websites. Citations are given for those materials 
that are in the public domain. Also included were documents that 
are not in the public domain, and which the authors of this paper 
are not legally authorised to make available. These include the 
internal records of WWARN’s board and scientific advisory 
committee meetings, minutes from meetings with WHO and 
other partner institutions, and correspondence between Oxford 
University, the Bill and Melinda Gates Foundation and other 
institutions. While these were made available to researchers for 
analysis, permission was not granted to publish documents relating 
to individuals who did not, at the time of the interaction in ques-
tion, grant consent to be identified. A list of the documents were 
coded in NVivo but can not be shared, along with their dates and 
content type (minutes of meetings, internal correspondence etc.) 
is available in the Dataverse repository cited in this statement. 
The terms of consent for interviews (also in the repository) also 
preclude the publication of interview tapes or transcripts. This 
step was taken to allow interviewees to speak openly about events 
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which involve their current or former employers or employees, 
research funders or grantees, and their scientific colleagues and 
rivals, without fear of reprisal. The Oxford Tropical Research 
Ethics Committee accepted these provisions, and further required 
that a list of potential interviewees be removed from the study 
protocol, to further protect anonymity. The authors will be happy 
to run specific queries derived from the coding tree, and provide 
appropriately anonymised/redacted results from the records review 
and interviews to readers on request. Please send query requests 
stating your institutional affiliation and the reason for the request to 
Oxford Tropical Research Ethics Committee (oxtrec@admin.ox.ac.
uk) quoting reference 593-16. The ethics committee will pass those 
requests it considered reasonable to the corresponding author for 
execution.
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This article investigates the sociocultural context of the establishment, design and development of a
global epidemiological data sharing initiative — the WorldWide Antimalarial Resistance Network
(WWARN) — from its beginnings over a decade ago until about a year ago.
It highlights that
data sharing requires dedicated infrastructure, including relevant standards and standard-aware
tools
designing this infrastructure and the associated policies requires engagement with all relevant
stakeholders
developing the above takes time and requires stable funding, including for the stakeholders
involved
buy-in from stakeholders additionally requires significant cultural changes within the research and
policy ecosystem in terms of how data sharing and the reuse of shared data and tools are valued
(especially in epidemiology, but also beyond).
None of these points are particularly new, but spelling them out on the basis of a concrete example like
WWARN and enriching them with sound bites — e.g. “Seven years ago, "data sharing" was a swear
word.” — is useful both for conversations within a given field (in this case epidemiology) and across fields.
The main strength of the paper lies in weaving in the often-neglected concept of equity, e.g. by giving
voice to representatives from malaria-endemic countries (i.e. mostly in lower and middle income settings)
and by discussing
the need for capacity building in such countries in terms of analyzing and otherwise utilizing data
pooled across multiple countries
the various direct and indirect interactions between single-country and multi-country studies
the role of mediators like the World Health Organization
the role of WWARN study sections as well as
some generic and specific inequalities in research funding, publishing and assessment.
The three main sources of the information presented are
a set of documents from WWARN and its partners as well as individuals involved
a set of interviews with individuals who are or have been involved with WWARN internally or
externally
a witness seminar that brought some of those individuals together to discuss themes emerging
from preliminary analysis of the documents and the set of individual interviews.
Basically none of these key sources have been shared (for justified privacy reasons), which naturally
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 Basically none of these key sources have been shared (for justified privacy reasons), which naturally
limits the reproducibility of the study. However, the authors document their sources' metadata in sufficient
detail to allow the reader to follow and evaluate the logic of the overall narrative as well as some of its
highlighted details, e.g. the differences of perspectives of the different stakeholders, and the change of
focus of the network from policy-oriented to research-oriented.
The study was qualitative in nature, so there is basically no statistical analysis. It also looked at the
WWARN case study almost in isolation, which limits the generalizability of the conclusions in principle, but
as WWARN's approach itself is now being generalized to other epidemiological use cases in the
framework of the newly established Infectious Diseases Data Observatory (IDDO, a WWARN umbrella),
this provides fertile ground for testing the validity of the paper's conclusions in other epidemiological
contexts like schistosomiasis, Ebola and visceral leishmaniasis.
Overall, I found the paper well written, and in the few cases where I found something that would benefit
from corrections, additions or clarification, I left a comment as part of my annotations of the paper, which
are accessible via   . None ofhttps://via.hypothes.is/https://wellcomeopenresearch.org/articles/2-63/v1
these would preclude approval here in Wellcome Open Research, but I would still like to encourage the
authors to address them in a revised version of the manuscript.
One point I did not mention in my annotations is the lack of visuals. While not essential, it would have
been useful to have some visual representation of the kinds of data that are now shared through
WWARN/ IDDO, as well as of the way(s) in which they were shared (privately or more broadly) before
WWARN, over the course of WWARN development and now through the WWARN/ IDDO system. This
can help the reader, but it can also help to attract new readers from within or near the paper's target group
of "researchers who share data, or are contemplating doing so".
For my notes on drafting this review, see   .https://github.com/Daniel-Mietchen/ideas/issues/494
This review is licensed CC0, as per   .http://creativecommons.org/publicdomain/zero/1.0/deed.en
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
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Are the conclusions drawn adequately supported by the results?
Yes
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some overlap of our respective work with regards to data sharing in public health emergencies. She is
also involved in the organization of a Wellcome-funded workshop on data sharing in low and middle
income countries later this month, which I am planning to attend.
Referee Expertise: Data sharing policies and infrastructure
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 06 September 2017Referee Report
doi:10.21956/wellcomeopenres.13272.r25063
   Kobus Herbst
Africa Health Research Institute, Durban, South Africa
This is a well researched and written report on the complexities involved in sharing public health data. The
investigators went to considerable lengths in researching the process leading up to and including the
actual sharing of WWARN data.
Although the authors acknowledge the limitation of the study as being limited to only data sharing
initiative, the study nevertheless provides several valuable insights into the complexities involved in data
sharing initiatives of this kind.
Their findings certainly echo my own experience with sharing INDEPTH data through the
Wellcome-funded iSHARE2 inititiative.
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